Financials Shanghai Aladdin Biochemical Technology Co.,Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
11.09 ^CNY	-0.09%		+0.45%	-18.97%

Apr. 29	Shanghai Aladdin Biochemical Technology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 19	Shanghai Aladdin Biochemical Technology Co.,Ltd. agreed to acquire 51% stake in Shanghai Yuanye Biotechnology Co., Ltd. for CNY 180 million from Cui Yuanyuan and Tan Xiaoyong.	CI

Fiscal Period: December	2022	2023	2024	2025	2026
Capitalization ¹	5,108	3,796	3,076	-	-
Enterprise Value (EV) ¹	5,108	3,796	3,076	3,076	3,076
P/E ratio	54 x	39.9 x	12.4 x	9.64 x	-
Yield	-	-	-	-	-
Capitalization / Revenue	-	9.42 x	6.01 x	4.65 x	3.85 x
EV / Revenue	-	9.42 x	6.01 x	4.65 x	3.85 x
EV / EBITDA	-	33.3 x	23.8 x	18 x	14.4 x
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Price to Book	-	3.66 x	2.82 x	2.59 x	2.35 x
Nbr of stocks (in thousands)	276,961	277,382	277,384	-	-
Reference price ²	18.44	13.69	11.09	11.09	11.09
Announcement Date	2/27/23	2/24/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2022	2023	2024	2025	2026
Net sales ¹	-	402.9	512	661	800
EBITDA ¹	-	113.9	129	171	213
EBIT ¹	-	95.2	140	196	242
Operating Margin	-	23.63%	27.34%	29.65%	30.25%
Earnings before Tax (EBT)	-	-	-	-	-
Net income ¹	95.38	85.83	177.1	227.6	-
Net margin	-	21.3%	34.59%	34.44%	-
EPS ²	0.3418	0.3429	0.8929	1.150	-
Free Cash Flow	-	-	-	-	-
FCF margin	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	2/27/23	2/24/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-
Net Cash position	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow	-	-	-	-	-
ROE (net income / shareholders' equity)	-	9.27%	11.8%	13.4%	13.6%
ROA (Net income/ Total Assets)	-	5.57%	7.2%	8.3%	9.5%
Assets ¹	-	1,541	2,460	2,742	-
Book Value Per Share ²	-	3.740	3.930	4.290	4.720
Cash Flow per Share	-	-	-	-	-
Capex ¹	-	45.7	90	63	54
Capex / Sales	-	11.34%	17.58%	9.53%	6.75%
Announcement Date	2/27/23	2/24/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.09 CNY

Average target price

12.14 CNY

Spread / Average Target

+9.49%

	1st Jan change	Capi.
SHANGHAI ALADDIN BIOCHEMICAL TECHNOLOGY CO.,LTD.	-18.97%	425M
MODERNA, INC.	+43.36%	58.06B
IQVIA HOLDINGS INC.	-5.31%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B
BIO-TECHNE CORPORATION	+0.04%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.12%	12B
MEDPACE HOLDINGS, INC.	+26.04%	11.92B